Trinity Biotech

TRIB

----

Current ValuationThe current P/E ratio is -4.10, below the reasonable range, cheaper than 93.86% of the time in the past 5 years, and the industry ranks 110/173, the industry Median -0.86.

-4.1xP/E

Stock price$8.19Earnings per share$-2.00

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.

013263952

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.

0x30x60x90x120x150x

P/E ratio
Name/Symbol
BAXUSBaxter	-12.15x	141.71%	$12.92B
GKOSUSGlaukos	-52.37x	75.37%	$9.85B
TFXUSTeleflex	-5.33x	118.39%	$5.49B
IRTCUSIRhythm	-259.03x	71.47%	$3.61B
PLSEUSPulse Biosciences	-42.36x	26.85%	$3.39B
AXGNUSAxogen	-61.63x	16.18%	$2.07B
BFLYUSButterfly Network	-26.58x	31.45%	$1.99B
ASSTUSStrive	-3.25x	63.23%	$3.17B
NVCRUSNovocure	-11.67x	1.23%	$1.73B
KMTSUSKestra Medical Tech	-11.48x	0.94%	$1.72B
ATECUSAlphatec	-14.62x	41.67%	$1.61B
DRTSUSAlpha Tau Medical	-12.59x	--	$1.17B
ENOVUSEnovis	-1.04x	100.97%	$1.15B
TNDMUSTandem Diabetes	-18.00x	77.60%	$1.14B
AORTUSArtivion	-340.42x	266.67%	$1.09B
PRCTUSPROCEPT BioRobotics	-9.54x	3.47%	$1.05B
IARTUSIntegra LifeSciences	-144.54x	108.85%	$1.05B
CBLLUSCeribell	-15.12x	35.15%	$997.83M
BBNXUSBeta Bionics	-12.15x	11.45%	$886.49M
SIBNUSSI-BONE	-60.22x	8.85%	$881.13M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.